GGiantBullStocks

Haemonetics Corporation (HAE)

NYSE · Healthcare

$78.17+0.40%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$3.46B
P/E ratio
EPS
Volume
490,558
52-week high
52-week low
Open
$77.81
Day high
$79.57
Day low
$77.59

Financial highlights

Fiscal yearRevenueNet incomeEPS
2026$1.33B$97.31M$2.05
2025$1.36B$167.68M$3.31
2024$1.31B$117.56M$2.29
2023$1.17B$115.4M$2.24
2022$993.2M$43.38M$0.84

About Haemonetics Corporation

Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.

CEO
Christopher A. Simon
Employees
3,657
Country
US
IPO date
May 10, 1991

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Haemonetics Corporation's stock price today?
HAE is trading at $78.17 as of Jul 20, 2026.
What is Haemonetics Corporation's market cap?
Haemonetics Corporation (HAE) has a market capitalization of $3.46B.
Does Haemonetics Corporation pay a dividend?
Haemonetics Corporation did not pay a dividend in its most recent reported fiscal year.
What sector is Haemonetics Corporation in?
Haemonetics Corporation operates in the Healthcare sector.